Aurora Cannabis Inc. filings document its U.S. reporting as a Canadian foreign private issuer and the formal disclosure record for its medical cannabis operations. Recent Form 6-K reports furnish news releases, material change reports, sales agreements and offering documents tied to product launches, financial results, acquisitions, governance matters and capital-structure activity.
The filings include disclosure for an at-the-market common-share program under shelf registration documents, material change reports on corporate transactions, and exhibits incorporated by reference into Form F-10 and Form S-8 registration statements. They also record Aurora's operating updates across regulated cannabis markets, GMP-certified manufacturing network, shareholder voting matters and executive-level governance disclosures.
Aurora Cannabis Inc. completed the expansion of its Leuna, Germany, facility, now renamed Aurora Horizon. Aurora says cultivation capacity has increased and annual flower output is expected to more than double. The newly built areas recently received an expanded EU-GMP license from the State Office for Social Affairs, Youth and Health of Saxony-Anhalt.
Aurora says the site has adopted cultivation and post-harvest practices from its Canadian operations and proprietary genetics from Aurora Coast, its global R&D facility in British Columbia. The added capacity is expected to help meet growing demand for medical cannabis in Germany and other European markets. Aurora also says the facility will support local job creation and describes itself as one of only three in-country producers in Germany.
Aurora Cannabis Inc. (ACB) said Curaleaf revised its hostile take-over bid for all issued and outstanding Aurora common shares, with revised implied consideration of US$5.00 per share: 0.4013 Curaleaf subordinate voting shares plus US$1.00 in cash per Aurora share.
Aurora's Special Committee is reviewing the bid with its advisors before making a recommendation to the board. Executive Chairman and CEO Miguel Martin urged shareholders to take no action pending that formal recommendation; Aurora said the board's recommendation will be shared through a news release and Directors' Circular. Shareholders have until at least December 4, 2026, to consider their options under the revised expiry date.
Aurora Cannabis Inc. (ACB) is the target of Curaleaf Holdings, Inc.’s amended offer to purchase all issued and outstanding common shares, together with associated rights issued under Aurora’s shareholder rights plan. The revised consideration is US$1.00 in cash and 0.4013 of a Curaleaf subordinate voting share per Aurora common share, subject to adjustment as provided in the Notice of Variation. The expiry time has moved from 5:00 p.m. Mountain Time on December 1, 2026, to 11:59 p.m. Mountain Time on December 4, 2026, unless further extended, accelerated or withdrawn.
Aurora Cannabis Inc. (ACB) said Curaleaf intends to file a revised takeover bid with stated implied consideration of US$5.00 per Aurora share: 0.4013 Curaleaf subordinate voting shares plus US$1.00 in cash per Aurora share. Aurora said the announcement was not a formal revised bid and that it had not received the materials needed for a full evaluation.
Aurora said Curaleaf agreed to amend its bid circular to include pro forma financial statements and extend the offer expiry to 11:59 p.m. Mountain Time on December 4, 2026. The Special Committee of independent directors will review a formal revised offer once received and make a recommendation to the Board. Aurora said shareholders will be notified of the Board’s formal recommendation within 15 days. Aurora reiterated its recommendation that shareholders take no action at this time and wait for the Board’s recommendation.
Aurora Cannabis Inc. (ACB) reports a strategic business update centered on its global medical cannabis focus, highlighting the expected benefits of its accretive acquisition of Safari Flower Company and strong performance in key high-margin international markets such as Germany, Poland, the UK, Australia and New Zealand. Management states that the Safari acquisition adds critical EU-GMP certified capacity and, together with recent UK acquisitions, is expected to support reliable supply to meet growing patient demand in an estimated $9 billion global medical cannabis market.
Aurora reaffirms fiscal 2027 Q2 guidance for sequential growth in quarterly net revenue and adjusted EBITDA, reflecting its strategy to focus exclusively on global medical cannabis. The company cites a strong balance sheet with $149 million in cash as of June 30, 2026 and no debt, and notes its at-the-market equity program will only be used when the board determines it is in the company’s best interest.
Aurora Cannabis Inc. (ACB) reported the appointment of Faris El Refaie as Executive Vice President, Global Commercial, effective September 28, 2026. This is a newly created role overseeing Aurora’s global commercial function for its medical cannabis business across Canada, Europe, Australia, New Zealand and other international markets.
El Refaie brings 25 years of biopharmaceutical leadership with experience at JAMP Pharma Group, GSK and AstraZeneca, covering innovative medicines, oncology, specialty care, vaccines and consumer healthcare. Aurora states that this appointment supports its strategy to strengthen and accelerate commercial capabilities and expand its global medical cannabis footprint.
Aurora Cannabis Inc. (ACB) reports that it has received an unsolicited take-over proposal from Curaleaf Holdings Inc., described as a hostile bid, and that Aurora’s board has unanimously recommended that shareholders reject it. A special committee of independent directors, with external financial and legal advisors, reviewed the proposal and concluded it is not in the best interests of Aurora or its shareholders. Aurora states it is debt free and reports holding approximately $149 million in cash as of June 30, 2026, while citing Curaleaf’s public disclosure of over $1 billion in debt. Based on the disclosed exchange ratio, Aurora indicates its shareholders would own about 7.7% of the equity and about 3.2% of the votes of the combined company due to Curaleaf’s multi-voting share structure. Aurora emphasizes its strategy as a focused global medical cannabis company with EU-GMP-certified production, international operations, and a balance-sheet position it views as supporting a standalone path.